Is Cellebrite DI (CLBT) Cheap As Lower 2026 Guidance And A CEO Change Hit?
Cellebrite DI guidance cut and CEO transition put the stock in focus
Cellebrite DI (NasdaqGS:CLBT) has drawn fresh attention after lowering its full year 2026 revenue outlook and confirming an internal CEO transition that installs Shiven Ramji as chief executive and board member.
See our latest analysis for Cellebrite DI.
At a share price of US$11.14, Cellebrite DI has seen short term momentum weaken, with the 7 day share price return down 29.94% and the year to date share price return down 37.56%. This is despite the 3 year total shareholder return of 50.95% and the 5 year total shareholder return of 11.74%, as investors digest the lower 2026 revenue guidance and the CEO transition.
If this shift in sentiment has you reassessing your watchlist, it can help to look at other AI driven software plays using the Simply Wall St screener for 75 profitable AI stocks that aren't just burning cash
Cellebrite DI’s sharp pullback after the guidance reset and CEO change could be read as a verdict on the business or as a swing in sentiment. The valuation now needs a closer look to see which it better reflects.
Most Popular Narrative: 27.5% Undervalued
At $11.14, Cellebrite DI is priced below the most widely followed fair value estimate of $15.36, which is built on detailed revenue and earnings forecasts.
The continued transition to a recurring, subscription-based revenue model, with over 90% of revenues now from subscriptions and growing SaaS/cloud penetration, improves revenue visibility, predictability, and operating leverage. This is already translating into higher EBITDA and free cash flow margins and is likely underappreciated in current valuations.
Curious what powers that $15.36 fair value for Cellebrite DI. The narrative hinges on brisk revenue expansion, rising margins, and a future earnings multiple usually reserved for premium software stocks.
Result: Fair Value of $15.36 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story for Cellebrite DI can change quickly if reliance on US federal contracts persists and mobile platform security limits lawful data access more quickly than expected.
Find out about the key risks to this Cellebrite DI narrative.
Another view on Cellebrite DI’s valuation
The first approach suggests Cellebrite DI is undervalued against a fair value of $15.36. The market ratio picture looks less forgiving. The current P/E of 48x is higher than both the US Software industry at 31.6x and peers at 34x, and above an estimated fair ratio of 34.7x. That gap points to valuation risk if growth or margins fall short. Which signal do you think deserves more weight right now?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
The mixed signals around Cellebrite DI’s valuation and outlook leave plenty of room for different interpretations, so it pays to review the data yourself and act while sentiment is still unsettled by weighing up the 4 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Cellebrite DI?
If Cellebrite DI has you rethinking your next move, do not stop here. Use focused stock lists to spot opportunities before they become crowded trades.
- Target potential value opportunities early by scanning companies that appear mispriced on quality and fundamentals using the 52 high quality undervalued stocks.
- Strengthen your watchlist with businesses that pair income potential and resilience through the 10 dividend fortresses.
- Reduce surprise risks by concentrating on companies with cleaner finances through the solid balance sheet and fundamentals stocks screener (50 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com